ArticleMolecular cancer2006
Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays.
Article in Molecular cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- β-Catenin-Associated Wnt Signaling and Tumor Microenvironment Markers in Basal Cell Carcinoma Subtypes.Journal of clinical medicine · 2026Article
- Investigation of radiation-induced DNA damage repair-related genes as diagnostic biomarkers for radiation.Journal of radiation research · 2025Article
- Innovations in Skin Cancer Nanotechnology: A Comprehensive Review.Pharmaceutical nanotechnology · 2025Review
- Illuminating Hope for Tumors: The Progress of Light-Activated Nanomaterials in Skin Cancer.International journal of nanomedicine · 2025Review
- Article
- The Anticancer Activities of Natural Terpenoids That Inhibit Both Melanoma and Non-Melanoma Skin Cancers.International journal of molecular sciences · 2024Review
- Review
- Recent Advances in Phenolic Metabolites and Skin Cancer.International journal of molecular sciences · 2021Review
- The transcriptional landscape analysis of basal cell carcinomas reveals novel signalling pathways and actionable targets.Life science alliance · 2021Article
- Xeroderma Pigmentosum C: A Valuable Tool to Decipher the Signaling Pathways in Skin Cancers.Oxidative medicine and cellular longevity · 2021Review
- Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma.The British journal of dermatology · 2019Article
- Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Review
- Anaplastic Lymphoma Kinase in Cutaneous Malignancies.Cancers · 2017Review
- Identification of a six-lncRNA signature associated with recurrence of ovarian cancer.Scientific reports · 2017Article
- Nucleotide Excision Repair and Vitamin D--Relevance for Skin Cancer Therapy.International journal of molecular sciences · 2016Review
- TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.The Journal of investigative dermatology · 2014Article
- Evasion of p53 and G2/M checkpoints are characteristic of Hh-driven basal cell carcinoma.Oncogene · 2014Article
- GLI2 induces genomic instability in human keratinocytes by inhibiting apoptosis.Cell death & disease · 2014Article
- Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma.Oncotarget · 2013Article
- Correlation of Global MicroRNA Expression With Basal Cell Carcinoma Subtype.G3 (Bethesda, Md.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSkin cancer accounts for 1/3 of all newly diagnosed cancer. Although seldom fatal, basal cell carcinoma (BCC) is associated with severe disfigurement and morbidity. BCC has a unique interest for researchers, as although it is often locally invasive, it rarely metastasises. This paper, reporting the first whole genome expression microarray analysis of skin cancer, aimed to investigate the molecular profile of BCC in comparison to non-cancerous skin biopsies. RNA from BCC and normal skin specimens was analysed using Affymetrix whole genome microarrays. A Welch t-test was applied to data normalised using dCHIP to identify significant differentially-expressed genes between BCC and normal specimens. Principal component analysis and support vector machine analysis were performed on resulting genelists, Genmapp was used to identify pathways affected, and GOstat aided identification of areas of gene ontology more highly represented on these lists than would be expected by chance.
resultsFollowing normalisation, specimens clustered into groups of BCC specimens and of normal skin specimens. Of the 54,675 gene transcripts/variants analysed, 3,921 were differentially expressed between BCC and normal skin specimens. Of these, 2,108 were significantly up-regulated and 1,813 were statistically significantly down-regulated in BCCs.
conclusionFunctional gene sets differentially expressed include those involved in transcription, proliferation, cell motility, apoptosis and metabolism. As expected, members of the Wnt and hedgehog pathways were found to be significantly different between BCC and normal specimens, as were many previously undescribed changes in gene expression between normal and BCC specimens, including basonuclin2 and mrp9. Quantitative-PCR analysis confirmed our microarray results, identifying novel potential biomarkers for BCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.